Feb. 23, 2021

Russia's Sputnik COVID19 Vaccine Trial - Efficacy and Limitations #9

Russia's Sputnik COVID19 Vaccine Trial - Efficacy and Limitations  #9

Russia's Sputnik COVID19 Vaccine Trial - Efficacy and Limitations The Russian Sputnik COVID19 vaccine interim analysis has been published in the prestigious medical journal The Lancet Efficacy is comparable to vaccines like the Pfizer/BioNTech and...


Russia's Sputnik COVID19 Vaccine Trial - Efficacy and Limitations

  • The Russian Sputnik COVID19 vaccine interim analysis has been published in the prestigious medical journal The Lancet
  • Efficacy is comparable to vaccines like the Pfizer/BioNTech and Moderna vaccines
  • But there are some serious concerns with the study and the published data reducing the usefulness of this vaccine and to whom it can be used
  • You don’t want to miss this episode

 GET THE ABSTRACT SCREENING TOOL

It can be a challenge to screen papers for clinical relevance. As we go beyond the abstract in this podcast, we have created a screening tool you can use when reading an abstract from a clinical research paper.

Using that tool enables you to quickly screen an abstract from a medical journal for clinical relevance selecting only those you want to read. At the same time, you will know why you skipped the rest. Get it at our website https://www.precision-evidence.com 

 LINKS:

The Sputnik COVID19 Vaccine trial in the Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext 

Precision Evidence #8: “Critical Appraisal of the Moderna COVID19 Vaccine Trial”

 https://www.precision-evidence.com/8 

Precision Evidence #6: “Covid-19 Vaccines Trials: Understanding the First Published Results”

 https://www.precision-evidence.com/6 

Precision Evidence #5: “Covid-19 Vaccines Trials and Press Releases – Looking Beyond the Efficacy”

 https://www.precision-evidence.com/5 

 

NOTES:

  • The interim analysis of the Russian Sputnik COVID19 vaccine is published in The Lancet
  • It demonstrates efficacy at 94.6% which is comparable to the Pfizer/BioNTech and Moderna vaccine interim analysis
  • Safety is comparable as well
  • There are, however,  when scrutinizing the study, some serious concerns with impact on the usefulness of the vaccine and reducing the precision of the evidence

 Contact us at email: podcast@precision-evidence.com,

Twitter @PrecisionEBM,

You can learn more at our website, where you can also leave us a voice message 

Website: www.precision-evidence.com

Hosts:

Dr. Kim Kristiansen, M.D: @KKristiansenMD

JG Staal: @HealthyEvidence

 

Music thanks to mixkit.co